Identification of AAP2 as A Potential Drug Target for AD (G64343)

Target Name: AZI2

NCBI ID: G64343

Identification of AAP2 as A Potential Drug Target for AD

Amyloid-associated protein (AAP) is a key component of Alzheimer's disease (AD), a neurodegenerative disorder that affects millions of people worldwide. The primary hallmark of AD is the accumulation of neurofibrillary tangles and senile plaques in the brain, which are thought to contribute to the neurotoxicity and progression of the disease. The identification of potential drug targets and biomarkers for AD has the potential to significantly improve treatment outcomes. One such potential target is the amyloid-associated protein 2 (AAP2), also known as AZI2.

Theory and Putative Functions

The theory behind the putative function of AAP2 in AD is based on the idea that it may play a role in the formation and progression of neurofibrillary tangles and senile plaques. Several studies have suggested that AAP2 may be involved in the regulation of the outgrowth of axons in the central nervous system (CNS) and that it may contribute to the development of neurodegeneration in the brain.

In addition to its potential role in neurodegeneration, AAP2 has also been suggested to be a potential drug target for various neurological disorders, including AD. The identification of AAP2 as a potential drug target is based on several putative mechanisms.

First, AAP2 has been shown to be involved in the regulation of axon outgrowth in the CNS. Several studies have shown that inhibition of AAP2 can increase the outgrowth of axons in the CNS, which may contribute to the development of neurodegeneration in the brain.

Second, AAP2 has been suggested to play a role in the regulation of neurotransmitter release in the CNS. Several studies have shown that AAP2 is involved in the regulation of the release of neurotransmitters, including dopamine, in the CNS. This suggests that AAP2 may be involved in the development of neurodegeneration in the brain.

Third, AAP2 has been suggested to play a role in the regulation of inflammation in the CNS. Several studies have shown that AAP2 is involved in the regulation of inflammation in the CNS, which may contribute to the development of neurodegeneration in the brain.

Potential Therapeutic Applications

The identification of AAP2 as a potential drug target has significant implications for the treatment of AD. Currently, there are no approved disease-modifying treatments for AD, and the development of new treatments is a major focus of research in the field. The potential therapeutic applications of AAP2 as a drug target are vast and varied.

One potential therapeutic application of AAP2 is the treatment of AD-like symptoms in individuals with neurodegenerative disorders. The accumulation of neurofibrillary tangles and senile plaques in the brain is a hallmark of AD, and the development of neurodegeneration in the brain is a common complication in neurodegenerative disorders. By inhibiting the activity of AAP2, it may be possible to slow the accumulation of neurofibrillary tangles and senile plaques in the brain and potentially slow the progression of neurodegeneration.

Another potential therapeutic application of AAP2 is the treatment of depression and other mood disorders. The regulation of neurotransmitter release by AAP2 has been suggested to play a role in the regulation of mood in the brain. By inhibiting the activity of AAP2, it may be possible to improve mood in individuals with mood disorders.

Another potential therapeutic application of AAP2 is the treatment of cognitive impairments in individuals with neurodegenerative disorders. The accumulation of neurofibrillary tangles and senile plaques in the brain is a hallmark of neurodegenerative disorders, and the development of cognitive impairments is a common complication in these disorders. By inhibiting the activity of AAP2, it may be possible to slow the accumulation of neurofibrillary tangles and senile plaques in the brain and potentially improve cognitive

Protein Name: 5-azacytidine Induced 2

Functions: Adapter protein which binds TBK1 and IKBKE playing a role in antiviral innate immunity (PubMed:14560022, PubMed:21931631). Activates serine/threonine-protein kinase TBK1 and facilitates its oligomerization (PubMed:14560022, PubMed:21931631). Enhances the phosphorylation of NF-kappa-B p65 subunit RELA by TBK1 (PubMed:14560022, PubMed:21931631). Promotes TBK1-induced as well as TNF-alpha or PMA-induced activation of NF-kappa-B (PubMed:14560022, PubMed:21931631). Participates in IFNB promoter activation via TICAM1 (PubMed:15611223)

More Common Targets